Long-term prevention of aneuploidy in human pluripotent stem cells by fine-tuning GSK3 activity

This study demonstrates that supplementing human pluripotent stem cell cultures with a low dosage of the GSK3 inhibitor CHIR99021 prevents long-term aneuploidy and ultra-fine chromosome bridges by fine-tuning WNT signaling, thereby preserving genomic stability and pluripotency for over 30 passages.

The Gist

The Big Picture: The "Glitchy" Stem Cell Factory

Imagine human pluripotent stem cells (hPSCs) as master builders in a construction factory. These cells are special because they can turn into any type of cell in the human body (heart, brain, skin). Scientists want to use them to grow new organs or repair damaged tissues.

However, there is a major problem: The factory is glitching.

Every time these cells divide to make more copies of themselves (a process called "passaging"), they start making mistakes. Sometimes they lose a blueprint (a chromosome), and sometimes they gain an extra one. This is called aneuploidy.

• The Analogy: Imagine a photocopier that is supposed to copy a 46-page document. After a few hundred copies, the machine starts skipping pages or adding random extra pages. If you try to build a house with these faulty blueprints, the house will collapse.

This "glitch" happens because the cells are under replication stress. Think of this like a factory worker trying to run a marathon while carrying a heavy backpack. They are moving too fast, their DNA is getting damaged, and they are making errors.

The Old Solution: Giving Them a Snack

Previously, scientists tried to fix this by giving the cells a "snack" called nucleosides.

• The Analogy: If the worker is tired because they ran out of energy, you give them an energy bar (nucleosides) to help them finish the job.
• The Result: It helped a little bit, but it didn't stop the machine from making structural errors. The worker was still rushing, and the blueprints were still getting torn up.

The New Discovery: Tuning the Engine (The "Goldilocks" Zone)

The researchers in this paper found a smarter way to fix the factory. They realized that the cells are being controlled by a signaling system called WNT.

• The Analogy: Think of WNT as the gas pedal of the cell.
  • If you press the gas too hard (too much WNT), the cells rush and differentiate (turn into specific cells like skin or muscle) before they are ready.
  • If you don't press the gas at all, the cells get stuck and stressed.
  • The scientists found that they needed to fine-tune the gas pedal. They needed just a tiny amount of pressure to keep the engine running smoothly without speeding up too much.

They used a drug called CHIR99021 (a GSK3 inhibitor) to do this. It acts like a cruise control for the cell's DNA copying machine.

What Happened When They Used the "Cruise Control"?

The team grew stem cells for a long time (30 generations, which is like a human living for 30 years) under two conditions:

1. Normal conditions (or with the "snack"): The cells started making massive mistakes. By the end, nearly 30% of the cells had the wrong number of chromosomes. They also developed "ultra-fine bridges"—tiny, invisible threads of unreplicated DNA that snapped during cell division, causing further damage.
2. With the "Cruise Control" (Low dose CHIR99021): The cells stayed healthy!
   • They kept their correct number of chromosomes (euploidy).
   • They didn't turn into other cell types; they stayed as master builders.
   • Crucially: They stopped making those "ultra-fine bridges." The DNA finished copying completely before the cell divided, so there were no broken threads.

Why This Matters

This discovery is a game-changer for two reasons:

1. Safety for Medicine: If we want to use stem cells to cure diseases, we can't use "glitchy" cells. This new method allows scientists to grow huge batches of perfect, healthy stem cells without having to pick through them one by one to find the good ones. It's like upgrading the factory so every product coming off the line is perfect.
2. New Understanding of Errors: The study found a new type of damage (the ultra-fine bridges) that we didn't know was happening. It turns out that just giving the cells "snacks" (nucleosides) isn't enough to fix the root cause; you have to tune the engine (WNT signaling) correctly.

The "Goldilocks" Conclusion

The paper concludes that WNT signaling follows the "Goldilocks Principle":

• Too much activity = Chaos and differentiation.
• Too little activity = Stress and errors.
• Just the right amount (fine-tuned) = Perfect, stable, healthy stem cells.

In short: By adding a tiny, precise amount of a common drug to the stem cell food, scientists can stop the cells from breaking their own blueprints, making them much safer and more reliable for future medical treatments.

Technical Summary

1. The Problem

Human pluripotent stem cells (hPSCs) are vital for regenerative medicine and developmental modeling. However, their clinical and research utility is severely hampered by chromosomal mosaicism (the coexistence of euploid and aneuploid cells).

• Instability: Cultured hPSCs rapidly acquire chromosome gains or losses (aneuploidy) and structural aberrations due to high replicative stress and errors in chromosome segregation.
• Consequences: This leads to the overgrowth of specific aneuploid clones (e.g., gains in chromosomes 1, 8, 12, 17, 20), which alters differentiation potential and necessitates laborious single-clone screening rather than bulk expansion.
• Limitations of Current Solutions: Previous strategies to mitigate this involved supplementing cultures with nucleosides to replenish nucleotide pools and alleviate replication stress. However, recent evidence suggests nucleosides may not ensure timely DNA replication completion before mitosis, failing to prevent all forms of genomic instability.

2. Methodology

The study utilized human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs, lines H1 and H9) cultured in standard E8 media.

• Experimental Design: Cells were passaged for over 30 passages (approx. 90 days) under different conditions:
  • Control: Standard E8 media.
  • Nucleoside Treatment: E8 + 20 µM nucleoside mix.
  • GSK3 Inhibition: E8 supplemented with varying concentrations of the GSK3 inhibitor CHIR99021 (ranging from 10 nM to 500 nM).
• Key Assays:
  • Pluripotency & Differentiation: qRT-PCR for markers (NANOG, T/Brachyury) and lineage specification assays to ensure cells retained primed pluripotency and did not differentiate prematurely.
  • Chromosome Segregation: Immunofluorescence of anaphase cells to quantify lagging chromosomes (using CENPC/CREST staining).
  • Karyotyping: Metaphase spreads analyzed via KaryoFish/M-FISH to detect whole-chromosome aneuploidy.
  • Structural Aberrations: Detection of Ultra-Fine Bridges (UFBs) using BLM (Bloom syndrome protein) staining and identification of unreplicated DNA in G2/M via EdU incorporation and pH3 staining.
  • Transcriptomics: RNA-seq to compare gene expression profiles between treated and untreated long-term cultures.

3. Key Contributions

• Discovery of a "Goldilocks" Mechanism: The authors demonstrate that WNT signaling must be finely tuned (neither too high nor too low) to maintain genome stability. High WNT activation drives differentiation, while low/no activation allows replication stress to accumulate.
• Identification of a Novel Mitotic Defect: The study characterizes a previously uncharacterized phenotype in long-term cultured hPSCs: the formation of ultra-fine DNA bridges (UFBs) during anaphase caused by unreplicated DNA, leading to copy-number variations (CNVs).
• Superiority of GSK3 Inhibition over Nucleosides: The paper establishes that while nucleosides address nucleotide pool depletion, they fail to prevent UFBs or ensure timely replication completion. In contrast, low-dose GSK3 inhibition addresses the root cause of replication stress management more effectively.

4. Key Results

• Dose-Dependent Effects of CHIR99021:
  • 500 nM: Induced rapid differentiation (exit from pluripotency).
  • 10–100 nM: Maintained homogenous pluripotent colonies without differentiation markers (NANOG remained high; T remained low) for 30+ passages.
• Prevention of Aneuploidy:
  • Control hPSCs showed a dramatic increase in anaphase lagging chromosomes (reaching ~23% at passage 30) and aneuploidy rates (rising from 8% to 29%).
  • 100 nM CHIR99021 completely prevented this increase, maintaining aneuploidy rates at baseline levels comparable to early passages.
  • Nucleoside supplementation reduced lagging chromosomes but was less effective than CHIR99021 in preventing the overall accumulation of aneuploidy.
• Prevention of Ultra-Fine Bridges (UFBs):
  • Long-term control cultures exhibited a high proportion of UFBs (indicating unreplicated DNA).
  • Crucially, only 100 nM CHIR99021 (not nucleosides) prevented the formation of UFBs. This suggests GSK3 inhibition promotes the completion of DNA replication prior to G2/M transition, whereas nucleosides do not.
• Genomic Integrity: RNA-seq confirmed that cells treated with 100 nM CHIR99021 retained their transcriptomic identity as primed pluripotent cells, with no significant differentiation signatures. A slight upregulation of APOBEC factors was noted, potentially linked to stress management.

5. Significance

• Protocol Optimization: The authors propose a simple, cost-effective reformulation of hPSC culture media: adding 100 nM CHIR99021 to standard E8 media. This allows for the safe, long-term bulk expansion of hPSCs without the risk of genomic drift.
• Clinical Relevance: By preventing both numerical (aneuploidy) and structural (CNVs, UFBs) chromosomal aberrations, this method significantly improves the safety profile of hPSCs for regenerative therapies and disease modeling.
• Broader Implications: The findings suggest that the "Goldilocks principle" of WNT/GSK3 signaling is critical for genome maintenance during S-phase. This mechanism may have applications beyond stem cells, potentially offering strategies to prevent chromosomal instability in early embryos (reducing IVF failure) or in cancer cells to prevent chemotherapy resistance.
• New Screening Standard: The study advocates for routine mapping of structural chromosomal alterations (like UFBs and CNVs) in addition to standard karyotyping for stem cell banking and therapeutic applications.